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Maturation is an essential step in the HIV-1 life-cycle. It
is the transition of immature, non-infectious virus parti-
cles to mature and infectious virions triggered by the
proteolytic cleavage of the precursor Gag and GagPol
polyproteins by the viral enzyme protease.
HIV-1 protease recognizes the asymmetric shape of
the peptide substrates, rather than a particular amino
acid sequence. These peptides have a super-ímposable
secondary structure, yielding a substrate “envelope”
which fits within the protease substrate-binding region.
There are however, a few differences between the sub-
strates in which amino acid side-chains protrude out of
the “envelope” which contribute to the different rates of
cleavage. Detailed knowledge of the structure of HIV
protease and its substrate has led to the development of
specific protease inhibitors (Pls), which have played a
major role in antiviral therapy. They bind protease with
high affinity but tend to occupy more space than the
natural substrates. Resistance to PI is usually a stepwise
process in which a substitution in the substrate-binding
cleft of the protease is observed first. This results in an
overall enlargement of the catalytic site and decreased
binding to the inhibitor and, in parallel, to some
decrease in binding to the natural substrate and to
decreased viral replication. Several studies have identi-
fied an association between selection of protease muta-
tions and mutations in the Gag substrate. We have
shown that substitutions in the NC/p1 cleavage site
alone, without any alterations in the viral protease were
selected during in vitro PI exposure. These NC/ p1
changes conferred PI resistance, which could directly be
related to increased gag processing. A detailed analysis
of clinical isolates of patients on PI therapy also indi-
cated that NC/p1 mutations strongly contribute to PI
resistance besides compensating for a loss in viral
replication.
A novel class of maturation inhibitors target the gag
structural proteins instead of the viral protease. Beviri-
mat (BVM; PA-457, MPC-4326) was the first of these
maturation inhibitors to go into clinical trials. The CA/
p2 cleavage site has been identified as the bevirimat tar-
get region by western-blotting and in vitro resistance
selection studies. Clinical studies (phase 2b) showed that
baseline polymorphisms slightly downstream of the CA/
p2 cleavage site, known as the QVT-motif also confer
resistance. We have shown that bevirimat resistance
mutations occur more frequently in PI resistant isolates
compared to isolates from PI treatment naive individuals
and this could mainly be attributed to mutations in the
QVT-motif. Furthermore, we have shown that PI resis-
tance mutations alter the bevirimat resistance profiles
selected in vitro and impact the level of bevirimat
resistance.
All these findings signify the strong interaction
between the viral protease and its substrate suggesting
that PI therapy can have important consequences for
future treatment with maturation inhibitors.
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